Among the most-read Vascular Specialist stories in December 2022 were the promising results from a postmarket surveillance study of a paclitaxel DCB; the Society for Vascular Surgery (SVS) paid tribute to the passing of former president James (Jimmy) S.T. Yao, MD; Monica Majumdar, MD, presenting data at the 2022 Eastern Vascular Society (EVS) annual meeting showing an increase in female-driven research and SVS reveal its top priorities for the coming decade.
A vascular surgery-specific composite frailty score was not associated with risk of surgical site infection in patients undergoing lower-extremity revascularization in a review carried out by Andrew Edsall, MD.
Christopher Audu, MD, profiles Ulka Sachdev-Ost, MD, and Anand Brahmandam, MD, for the new and innovative Journal of Vascular Surgery (JVS) internship program.
SVS members are mourning the death of James (Jimmy) S.T. Yao, MD, 88, former SVS president and Lifetime Achievement Award recipient. Yao died Tuesday, Dec. 20, in Chicago. He had been a very active member of SVS since 1974, holding many roles, including that of president in 1993.
4. Women’s Vascular Summit: Diving into issues around women’s vascular health and the female workforce
Ahead of The Women’s Vascular Summit 2023, meeting founder and course director Linda Harris, MD, tells Vascular Specialist about why the meeting came to be, and how it is being used to advance the cause of greater diversity and equity among the vascular workforce, and solve enduring disparities in vascular disease outcomes.
5. Paclitaxel DCB performs well in ‘challenging anatomy’ of femoropopliteal in-stent restenosis, VQI registry data show
The IN.PACT Admiral DCB (Medtronic) shows promising results in treating femoropopliteal in-stent restenosis (ISR) in a SVS Vascular Quality Initiative (VQI) registry-based, postmarket surveillance study presented by Daniel Bertges, MD.
A significant proportion of patients enrolled in the BEST-CLI trial did not meet OMT guideline-based recommendations at the time of their entry into the study, co-principal investigator Matthew Menard, MD, told the 2022 New England Society for Vascular Surgery (NESVS).
Endologix announced in December that it has received Food and Drug Administration (FDA) approval for a premarket approval (PMA) supplement relating to the AFX2 system.
Monica Majumdar, MD, a general surgery resident at Tufts Medical Center in Boston, presented data on how vascular surgery compares to other specialities in the growth of gender diversity in published research. “Are we leaders in the field, or are we trailing?”
A new review textbook developed by a vascular surgery resident with the aim of helping fellow trainees prepare for milestones like the VSITE has accumulated sales of around 500 copies across some 14 different countries.
The Society for Vascular Surgery (SVS) Research Council updated its top 10 research priorities in December, originally published in 2011, with patient-centered outcomes and personalized vascular care at their core, and a new emphasis on healthcare disparities.